If you have been reading about Anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-15. Numbers and descriptions here follow the published literature rather than marketing material.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
=== Healthcare === The Ajinomoto Group's healthcare business is based on using the fermentation technology of amino acids. In 1956, Ajinomoto began producing the world's first amino acid infusion, enteral nutrition products, and crystalline amino acids that could be used as raw materials in pharmaceutical products. Currently, Ajinomoto manufactures around twenty kinds of amino acids at various factories overseas, including plants in Japan, the United States, Europe, and India. In 1995, Ajinomoto began selling an amino acid supplement called Amino Vital for professional sports athletes. In 2011, Ajinomoto began offering an "Amino Index" health checkup, which statistically analyzes the difference in amino acid concentrations between healthy individuals and adults suffering from cancer and other serious diseases to aid the early detection of cancer and other diseases. In addition to glutamates as a seasoning, the company also produces other amino acids such as L-Leucine, L-Tyrosine, Glycine, and L-Phenylalanine, which it markets as dietary supplements under the brand name AjiPure.
Crystallization analysis fractionation (CRYSTAF): instrument intended for the fast measurement of the chemical composition distribution (CCD) in polyolefins (crystallization analysis fractionation). Temperature rising elution fractionation (TREF): for the characterization of CCD in polyolefins. Crystallization elution fractionation (CEF): high-throughput chemical composition distribution analyzer by CEF TGIC: technique for the analysis of low crystallinity polyolefins implemented by a fully automated instrument. Molar mass distribution GPC-IR: high temperature gel permeation chromatography (GPC) for polyolefin molar mass distribution. It works with concentration and composition detectors (infrared), viscometer and light scattering. GPC One: GPC calculations software. Data Unit 200: signals device for gel permeation chromatography instruments. GPC-QC: simplified and fully automated GPC instrument aimed at control laboratories in polyolefin production plants. Intrinsic viscosity IVA: automated instrument for intrinsic viscosity analysis of polymers with dissolution temperature up to 200 °C. Bivariate distribution Cross-fractionation chromatography(CFC) instrument to analyze the polyolefin bivariate distribution by TREF and gel permeation chromatography. SGIC 2D: 3D results with the advantages of using an IR detector for this new tool aimed at polyolefin characterization. Preparative fractionation PREP mc2: preparative instrument to fractionate polymers by molar mass or composition (TREF or CRYSTAF).
=== Fibroblast growth factor === Platelet-derived growth factors (PDGFs) are polypeptides found in various tissues, including bone, where it was originally postulated that it could act as an autologous regulator of bone remodeling. This protein has been initially isolated in human platelets, and is composed of two different polypeptide chains A and B. The combination of these polypeptides form the homodimeric (AA) or (BB), or heterodimeric (AB) chains of PDGF. Fibroblast growth factor (FGF) signaling cascade is started by the binding of 2 growth factors to the FGFR. Dimerization takes place and initiates the transphosphorylation of each receptor. These phosphorylation sites act as docking sites for proteins so they may induce downstream signaling. These proteins consist of FRS2-alpha and PLC-gamma. FRS2-alpha acts as a scaffold protein to hold GAB1 and GRB2 which then proteins bind to SHP2 and SOS. These several proteins act together to activates the Ras pathway (induces cell proliferation and differentiation) and the PI3K pathway (induces survival and cell fate determination). On the other side of the dimerized receptors, PLC-gamma activates DAG and IP3 which yield PKC and calcium ions. PKC and calcium will ultimately induce morphology, migration, and adhesion.
== Awards == In 1980, she was the recipient of a Guggenheim Fellowship. Other honors include the Award for Distinguished Contributions to Psychology in the Public Interest of the American Psychological Association, the NYU Alumni Achievement Award, the Liberty Science Center Genius Award, the Distinguished Contributions of Basic Science to Applied Psychology award from the American Association of Applied and Preventive Psychology, the James McKeen Cattel Award, and the Gordon Allport Intergroup Relations Prize.
=== Diabetic ketoacidosis (DKA) === Diabetic ketoacidosis (DKA) is one of the life-threatening severe complications of diabetes that demands immediate attention and intervention. It is considered a medical emergency and can affect both patients with T1D (type 1 diabetes) and T2D (type 2 diabetes), but it is more common in T1D. DKA results from significantly low insulin levels due to various factors including undiagnosed diabetes (people who did not know they have diabetes), missed or delayed doses, insufficient insulin administration, or undergoing physiological stress (e.g. infection, surgery, Stroke, or trauma). Due to insulin absence, it simply triggers the release of counter-regulatory hormones resulting in serious health complications. This release prompts excessive free fatty acids (FFAs) production as a result of the adipose tissue exhibiting heightened activity of hormone-sensitive lipase. Subsequently, the liver turns fatty acid to ketone bodies for fuel, a process known as ketosis, which causes Ketonemia (high ketone level in the blood) that decreases the blood's pH, leading to DKA. While periodic ketosis is normal, but can become a serious problem if sustained. These hormones can also induce hyperglycemia (high blood glucose) by stimulating gluconeogenesis thereby increasing the renal glucose output. In addition to the endogenous renal glucose produced by the kidneys. The condition of high circulating concentrations of ketone bodies and hyperglycemia leads to osmotic diuresis, characterized by the excessive presence of glucose and ketones in the urine.
Sources: en.wikipedia.org
==== Stripping recycle process ==== The conventional recycle process for recovering and reusing the reactants has largely been supplanted by a stripping process, developed in the early 1960s by Stamicarbon in The Netherlands, that operates at or near the full pressure of the reaction vessel. It reduces the complexity of the multi-stage recycle scheme, and it reduces the amount of water recycled in the carbamate solution, which has an adverse effect on the equilibrium in the urea conversion reaction and thus on overall plant efficiency. Effectively all new urea plants use the stripper, and many total recycle urea plants have converted to a stripping process. In the conventional recycle processes, carbamate decomposition is promoted by reducing the overall pressure, which reduces the partial pressure of both ammonia and carbon dioxide, allowing these gasses to be separated from the urea product solution. The stripping process achieves a similar effect without lowering the overall pressure, by suppressing the partial pressure of just one of the reactants in order to promote carbamate decomposition. Instead of feeding carbon dioxide gas directly to the urea synthesis reactor with the ammonia, as in the conventional process, the stripping process first routes the carbon dioxide through the stripper. The stripper is a carbamate decomposer that provides a large amount of gas-liquid contact. This flushes out free ammonia, reducing its partial pressure over the liquid surface and carrying it directly to a carbamate condenser (also under full system pressure).
== Teleneurotherapy == Teleneurotherapy utilizes computers and communication technology to execute neurotherapy remotely. Organisms receive physical stimuli, such as sounds (through mechanoreceptors and mitochondria across different organ systems) and light (through photoreceptors located in the retina and mitochondria) that alter neuronal activity in specific brain zones. Research indicates that systematic physical stimuli produced by standard electronic devices, such as tablets and headphones, may treat online injured nervous systems by modulating neuronal plasticity. Teleneurotherapy "emulates the central parameters of natural brain stimulation during gestation." "Because natural neurostimulation contributes to the balanced development of the nervous system in fetuses with adequate biological sentience, the scaled parameters of these natural forces can potentially treat an injured nervous system in adults." Evidence suggests that teleneurotherapy can enable neurological treatment if it considers key parameters of the mother-fetus interaction that provide the therapeutic effect in case of a systematic impact. Recent research implemented the APIN method (see above) in the online treatment of patients with different neurological conditions, which showed significant therapeutic effects.
Hitler believed that as centuries passed, his huge domed assembly hall would acquire great holy significance and become a hallowed shrine as important to National Socialism as St. Peters in Rome is to Roman Catholicism. Such cultism was at the root of the entire plan. Nevertheless, Giesler remarked that Hitler never made plans for world domination and that to suggest as much is not only nonsense (Unsinn) but 'Speer Rubbish' (Speerlicher Quatsch).
MgCl2 → Mg(g) + Cl2(g) The temperatures at which this reaction is operated is between 680 and 750 °C. The magnesium chloride can be obtained using the Dow process, a process that mixes sea water and dolomite in a flocculator or by dehydration of magnesium chloride brines. The electrolytic cells are partially submerged in a molten salt electrolyte to which the produced magnesium chloride is added in concentrations between 6–18%. This process does have its share of disadvantages including production of harmful chlorine gas and the overall reaction being very energy intensive, creating environmental risks. The Pidgeon process is more advantageous regarding its simplicity, shorter construction period, low power consumption and overall good magnesium quality compared to the electrolysis method. In the United States, magnesium was once obtained principally with the Dow process in Corpus Christi TX, by electrolysis of fused magnesium chloride from brine and sea water. A saline solution containing Mg2+ ions is first treated with lime (calcium oxide) and the precipitated magnesium hydroxide is collected:
It is generally advised that when patients have a low initial CD4 T cell count and OI at the time of their HIV diagnosis, they receive treatment to control the OIs before HAART is initiated approximately two weeks later. This is true for most OIs, except for OIs involving the central nervous system.
Sources: en.wikipedia.org
=== As structural material === Iron is the most widely used of all the metals, accounting for over 90% of worldwide metal production. Its low cost and high strength often make it the material of choice to withstand stress or transmit forces, such as the construction of machinery and machine tools, rails, automobiles, ship hulls, concrete reinforcing bars, and the load-carrying framework of buildings. Since pure iron is quite soft, it is most commonly combined with alloying elements to make steel.
=== On the heart === Myostatin is expressed at very low levels in cardiac myocytes. Although its presence has been noted in cardiomyocytes of both fetal and adult mice, its physiological function remains uncertain. However, it has been suggested that fetal cardiac myostatin may play a role in early heart development. Myostatin is produced as promyostatin, a precursor protein kept inactive by the latent TGF-β binding protein 3 (LTBP3). Pathological cardiac stress promotes N-terminal cleavage by furin convertase to create a biologically active C-terminal fragment. The mature myostatin is then segregated from the latent complex via proteolytic cleavage by BMP-1 and tolloid metalloproteinases. Free myostatin is able to bind its receptor, ActRIIB, and increase SMAD2/3 phosphorylation. The latter produces a heteromeric complex with SMAD4, inducing myostatin translocation into the cardiomyocyte nucleus to modulate transcription factor activity. Manipulating the muscle creatinine kinase promoter can modulate myostatin expression, although it has only been observed in male mice thus far. Myostatin may inhibit cardiomyocyte proliferation and differentiation by manipulating cell cycle progression. This argument is supported by the fact that myostatin mRNA is poorly expressed in proliferating fetal cardiomyocytes. In vitro studies indicate that myostatin promotes SMAD2 phosphorylation to inhibit cardiomyocyte proliferation.
== Analysis == A wide variety of techniques can be used to analyze the interfacial layer, often SAXS, NMR, AFM, STM are used, but other methods, like measuring the refractive index can reveal information as well. Small-angle X-ray diffraction provides data about the size and dispersion of the nanoparticles, and gives information about the density of the interfacial layer. Because the amount of scattering is proportionate with the density. On top of this the thickness of the layer can be estimated. However a disadvantage is that SAXS is destructive. AFM and STM measurements can reveal information at atomic resolution about the structure and shape of the interfacial layer. This information is limited to the surface of the nanoparticle, as you can only probe the surface. Another drawback of STM is that it's only applicable if the interfacial layer is conducting. (Solid-state) NMR can be used to study the composition, short range ordering and dynamics in the interfacial layer. The dynamics can be studied over a wide range of timescales, which allows the intermolecular interactions, chemical reactions and transport phenomena to be analyzed.
Her two manuscripts on form A DNA reached Acta Crystallographica in Copenhagen on 6 March 1953, one day before Crick and Watson had completed their model. The X-ray diffraction images collected by Gosling and Franklin provided the best evidence for the helical nature of DNA. Before this, both Linus Pauling, Watson, and Crick had generated erroneous models with the chains inside and the bases pointing outwards. Her experimental results provided estimates of the water content of DNA crystals, and these results were most consistent with the three sugar-phosphate backbones being on the outside of the molecule. Franklin's X-Ray photograph showed that the backbones had to be on the outside. Although she at first insisted vehemently that her data did not force one to conclude that DNA has a helical structure, in the drafts she submitted in 1953 she argues for a double helical DNA backbone. Building on her manuscripts, she discovered that form A DNA had antiparallel backbones, which supported the double helical structure of DNA. She did this through identification of the space group for DNA crystals. This would go to help Watson and Crick decide to look for DNA models with two antiparallel polynucleotide strands. In summary, Watson and Crick had three sources for Franklin's unpublished data: 1) her 1951 seminar, attended by Watson, 2) discussions with Wilkins, who worked in the same laboratory with Franklin, 3) a research progress report that was intended to promote coordination of Medical Research Council–supported laboratories.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.